Soluble Neprilysin　― Cardiac Function and Outcome in Hypertrophic Cardiomyopathy ―

• Yoshihisa Akiomi

  Department of Cardiovascular Medicine, Fukushima Medical University Department of Advanced Cardiac Therapeutics, Fukushima Medical University

• Yokokawa Tetsuro

  Department of Cardiovascular Medicine, Fukushima Medical University Department of Pulmonary Hypertension, Fukushima Medical University

• Ichijo Yasuhiro

  Department of Cardiovascular Medicine, Fukushima Medical University

• Kimishima Yusuke

  Department of Cardiovascular Medicine, Fukushima Medical University

• Kanno Yuki

  Department of Cardiovascular Medicine, Fukushima Medical University

• Misaka Tomofumi

  Department of Cardiovascular Medicine, Fukushima Medical University Department of Advanced Cardiac Therapeutics, Fukushima Medical University

• Sato Takamasa

  Department of Cardiovascular Medicine, Fukushima Medical University

• Oikawa Masayoshi

  Department of Cardiovascular Medicine, Fukushima Medical University

• Kobayashi Atsushi

  Department of Cardiovascular Medicine, Fukushima Medical University

• Yamaki Takayoshi

  Department of Cardiovascular Medicine, Fukushima Medical University

• Sugimoto Koichi

  Department of Cardiovascular Medicine, Fukushima Medical University Department of Pulmonary Hypertension, Fukushima Medical University

• Kunii Hiroyuki

  Department of Cardiovascular Medicine, Fukushima Medical University

• Takeishi Yasuchika

  Department of Cardiovascular Medicine, Fukushima Medical University

抄録

Background:Circulating soluble neprilysin (sNEP) predicts outcome in heart failure (HF) patients with reduced ejection fraction (EF), but not in those with preserved EF. We examined sNEP in patients with hypertrophic cardiomyopathy (HCM), and their correlations with other biomarkers, cardiac function, and clinical outcome. Methods and Results:We examined the associations between sNEP and the laboratory and echocardiography parameters in the HCM patients (n=93). Regarding the laboratory data, sNEP had a significant positive correlation with B-type natriuretic peptide (BNP; R=0.326, P=0.003), but not with troponin I. As for the echocardiographic parameters, sNEP negatively correlated with left ventricular EF (R=−0.283, P=0.009) and right ventricular fractional area change (R=−0.277, P=0.012), but not with left ventricular mass. Next, we prospectively followed up on the patients for cardiac events, including worsening HF or cardiac death, and all-cause mortality. On Kaplan-Meier analysis (mean follow-up, 1,021 days), the cardiac event rate and all-cause mortality were similar between the higher sNEP group (sNEP ≥median level of 1.43 ng/mL, n=46) and lower sNEP group (sNEP <1.43 ng/mL, n=47). On Cox proportional hazard analysis, sNEP was not a predictor of cardiac event or all-cause mortality. Conclusions:Soluble neprilysin appears to correlate with BNP and cardiac systolic function, but it is not significantly associated with prognosis in HCM patients.

収録刊行物

• Circulation Reports

  Circulation Reports 1 (6), 261-267, 2019-06-10

  一般社団法人 日本循環器学会

キーワード

• Echocardiography
• Hemodynamics
• Hypertrophic cardiomyopathy
• Natriuretic peptide
• Neprilysin

詳細情報

• CRID: 1390564238098226944
• NII論文ID: 130007662188
• DOI: 10.1253/circrep.cr-19-0034
• ISSN: 24340790
• Web Site: https://www.jstage.jst.go.jp/article/circrep/1/6/1_CR-19-0034/_pdf
• 本文言語コード: en
• データソース種別:
  • JaLC
  • Crossref
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可